Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)

NCT03832738 is registered in ClinicalTrials.gov with Akros Pharma Inc. as lead sponsor.

NCT NCT03832738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03832738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of JTE-451 Administered for 16 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)
Lead sponsor
Akros Pharma Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 17, 2019
Completion date
March 13, 2020
Enrollment
152 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, psoriasis, skin diseases